FIT screening

Colorectal cancer (CRC) is one of the most frequently diagnosed cancers. The good news is that CRC incidence and mortality can be reduced significantly if detected early enough.

Faecal immunochemical tests (FIT) are non-invasive and can detect blood in stool invisible to the naked eye. Due to its simplicity, FIT is currently considered the best non-invasive test for CRC screening.

Invest a little time in your own health by taking the FIT to prevent or detect colon cancer early on.
For further information, please visit our ‘FIT for screening’ website www.fitscreening.eu/patients

 

 

Please select your country. This will keep you up to date with your country-specific information.

Genedrive®

  • Ideal for low throughput, decentralised laboratories
  • Minimal hands on time
  • Single button operation
  • Unambiguous diagnostic results, without the need for specialist knowledge or data interpretation
  • With no manual calibration or maintenance required

Documents

All
  • All
  • Brochure
Documents

Molecular Diagnostics at the point of need

Genedrive Diagnostics Ltd is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has received CE-IVD Certification.

Hepatitis C (HCV) is an international public health challenge, comparable to other major communicable diseases, including HIV, tuberculosis and malaria. It is estimated that 150–200 million people, or approximately 3% of the world's population, are living with chronic HCV, and more than 350,000 people die yearly from HCV related diseases. In 2016, WHO published the first global health sector strategy on Hepatitis with a goal of eliminating viral hepatitis as a major public health threat by 2030. New oral, well-tolerated treatment regimens can achieve cure rates of over 90% however access to rapid, inexpensive and accurate diagnostics are a critical bottleneck that must be addressed to eradicate HCV.

With the advent of new ‘curative’ direct acting antiviral treatments for Hepatitis C (HCV), genedrive and Sysmex believe that there is a major opportunity to support tackling the global burden of the disease if accurate, decentralised diagnostics can be used to identify those living with HCV and give them access to therapy. genedrive’s HCV test is the first to market as a decentralised qualitative molecular HCV test for use at the point of need. This agreement follows the recent CE-IVD Certification from the EU for Genedrive® HCV ID Kit, a qualitative molecular assay for HCV.
Genedrive® HCV ID Kit is a qualitative HCV assay, providing results within 90 minutes and the assay is performed on a portable molecular diagnostics platform.

Genedrive® is a registered product of genedrive plc www.genedrive.com

Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
See our collection
Company movie